Aggrega Pharma

What Aggrega Pharma does

Aggrega Pharma is a US-registered pharmaceutical consortium founded in 2019 by four European-based pharmaceutical manufacturers: Bluepharma (Portugal), Rafarm (Greece), Substipharm (France), and Welding (Germany). The company's stated purpose is to develop and commercialize a portfolio of generic drug products by leveraging the combined R&D, clinical, and manufacturing capabilities of its shareholders, who collectively generate over $500M in revenue, employ more than 1,200 people, operate in 60+ countries, and have completed 100+ global product launches.

The company's portfolio spans eleven generic drug products across a wide range of dosage forms, including extended-release and immediate-release oral solids, oral thin films, complex ophthalmic suspensions, sterile ophthalmic emulsions, ophthalmic ointments, high-potent oral solids, complex nasal sprays, and injectable solutions. Manufacturing is performed at FDA-inspected shareholder facilities in Coimbra (oral solid dose), Hamburg (niche/complex dosage forms), Paris (sterile injectable and ophthalmic), and Athens, with additional capacity sourced through a network of finished-dose CDMOs across Europe, North America, and Asia. Clinical study management is provided via the Blueclinical subsidiary.

Aggrega operates a sales-led, enterprise partnership go-to-market model, targeting pharmaceutical companies seeking to enhance their portfolios through co-development and co-investment deals. Revenue mechanics combine licensing/royalty structures with managed-services contract manufacturing, primarily through flexible, quote-based partnership agreements. The company initially focuses on the US market with plans to expand ex-US, and is selectively pursuing 505(b)(2) opportunities alongside its core generic franchise. Its primary disclosed commercialization partner is Xiromed, with whom it launched Ephedrine Sulfate Injection USP in the U.S. in 2023.

Name

Aggrega Pharma

Legal name

Aggrega Pharma LLC

Website

https://aggregapharma.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Aggrega Pharma is a US-registered consortium of four European pharmaceutical manufacturers (Bluepharma, Rafarm, Substipharm, Welding) that develops and commercializes generic drug products through flexible co-development partnerships with pharmaceutical companies seeking portfolio enhancement.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Drug product development
• Contract manufacturing
• Oral solid dosage
• Sterile injectables

Headquarters

HQ city

Ramsey

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Generic Drug Product Sales: Development, registration, supply and commercialization of generic drug products globally with focus on various dosage forms including niche, complex and high potent products
2. Co-development and Co-investment: Flexible commercial models for co-development and co-investment in generic drug products and select 505(b)2 opportunities with pharmaceutical partners
3. Contract Manufacturing Services: Development and commercial manufacturing services through shareholder network of FDA inspected facilities for finished dose products

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Aggrega Pharma develops, registers, supplies, and commercializes generic drug products on behalf of and in partnership with pharmaceutical companies. Its portfolio spans oral solids (extended and immediate release), oral thin films, high potent oral solids, ophthalmic suspensions/emulsions/ointments, complex nasal sprays, and injectable solutions. Offerings are delivered through flexible co-development, co-investment, and licensing arrangements supported by FDA-inspected shareholder manufacturing facilities and a global CDMO network.

Product overview

Aggrega Pharma is a pharmaceutical company created in 2019 by four European-based pharmaceutical companies (Bluepharma, Rafarm, Substipharm, and Welding) focused on enhancing partner portfolios through access to generic drug product opportunities. The company offers a portfolio of generic pharmaceutical products including various oral solids (Extended Release and Immediate Release), oral thin films, ophthalmic products (suspensions, emulsions, ointments), nasal sprays, and injectable solutions. The product pipeline includes products in early development, in development, ANDA submission stage, and approved/commercial stage. Manufacturing capabilities include FDA-inspected facilities for oral solid and sterile injectable/ophthalmic products across Europe.

Differentiator

Problem solved

Functional benefit

Products and services

• Extended Release Oral Solid Extended Release oral solid dosage form generic drug product manufactured at FDA-inspected shareholder facilities (Bluepharma), offered to pharmaceutical partners for commercialization.
• Immediate Release Oral Solid Immediate Release oral solid dosage form generic drug product manufactured at FDA-inspected shareholder facilities (Bluepharma), offered to pharmaceutical partners for commercialization.
• Oral Thin Film Oral thin film drug delivery system generic product developed and offered to pharmaceutical partners.
• Complex Ophthalmic Suspension Complex ophthalmic suspension formulation generic product, drawing on sterile manufacturing capabilities at Substipharm's FDA-inspected facility.
• Sterile Ophthalmic Emulsion Sterile ophthalmic emulsion generic product for eye treatment, manufactured at FDA-inspected sterile injectable/ophthalmic facilities (Substipharm).
• Ophthalmic Ointment Ophthalmic ointment generic product manufactured using shareholder sterile/ophthalmic capabilities.
• High Potent Oral Solid High potency oral solid dosage form generic drug product, leveraging niche and complex formulation capabilities across the shareholder network.
• Complex Nasal Spray Complex nasal spray delivery system generic drug product developed and offered to pharmaceutical partners.
• Injectable Solution Injectable solution generic drug product for parenteral administration, manufactured at FDA-inspected sterile injectable facilities (Substipharm). Ephedrine Sulfate Injection USP was commercially launched in the U.S. market through partner Xiromed in 2023.
• Contract Manufacturing Services Development and commercial manufacturing services for finished dose generic drug products, delivered through the shareholder network of FDA-inspected facilities (Bluepharma, Substipharm, Rafarm, Welding) and global CDMO partners.

Quantifiable outcome

• Combined 100+ global product launches
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• XiromedcoreStrategic or Co-development Partner · 1 January 2023Xiromed and Aggrega announced successful launch of Ephedrine Sulfate Injection USP in the U.S. market. This represents a product launch partnership where Xiromed commercializes products developed or supplied through the Aggrega network.
• BluepharmaflagshipStrategic or Co-development Partner · 1 January 2019Portuguese pharmaceutical company and founding shareholder. Provides extended and immediate release oral solid finished dose development and commercial manufacturing (FDA inspected), plus clinical study management through Blueclinical. Headquarters in Coimbra, Portugal.
• RafarmflagshipStrategic or Co-development Partner · 1 January 2019Greek pharmaceutical company and founding shareholder. Provides development and manufacturing capabilities. Located in Athens, Greece. Founded in 1955.
• SubstipharmflagshipStrategic or Co-development Partner · 1 January 2019French pharmaceutical company and founding shareholder. Provides sterile injectable and ophthalmic finished dose development and commercial manufacturing (FDA inspected). Located in Paris, France.
• WeldingflagshipStrategic or Co-development Partner · 1 January 2019German pharmaceutical company and founding shareholder. Develops, supplies and commercializes drug products (ex-US) with focus on niche, complex dosage forms. Located in Hamburg, Germany.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Patheon (Thermo Fisher CDMO services): Patheon, part of Thermo Fisher's pharma services business, is one of the largest pharmaceutical CDMOs offering oral solid dose, sterile fill-finish and complex formulation development. It is comparable as a broad incumbent in the CDMO angle of Aggrega's co-development/contract manufacturing model.
• Sandoz: Sandoz is the large Novartis-spin-off global generics and biosimilars leader. It is comparable to Aggrega Pharma as a broad incumbent covering oral solids, injectables and complex generics across major regulated markets, making it both a competitor for portfolio partners and a benchmark for U.S. commercial reach.
• Aurobindo Pharma: Aurobindo is a large Indian-headquartered global generics manufacturer with substantial U.S. presence across oral solids, injectables and complex generics. It is comparable as a broad incumbent with vertically integrated API-to-finished-dose capabilities similar to Aggrega's shareholder network.
• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a broad U.S. commercial footprint across oral solids, injectables and specialty generics. It is a broad-incumbent benchmark and competitor for any U.S.-targeted portfolio partnership Aggrega pursues.

Direct peers

• Lupin Pharmaceuticals: Lupin is a major India-headquartered generic pharma company with a meaningful U.S. presence across complex generics and specialty dosage forms. It is comparable as a peer expanding from generic manufacturing into higher-complexity products and select 505(b)2-style opportunities.
• Amneal Pharmaceuticals: Amneal is a U.S.-headquartered generic and specialty pharma with manufacturing across oral solids, injectables and complex dosage forms plus biosimilars. Its hybrid model—internal manufacturing plus partnerships and co-development—closely parallels Aggrega's consortium-based approach.
• Hikma Pharmaceuticals: Hikma is a publicly traded generic and specialty pharma company with manufacturing across oral solids, injectables and ophthalmics and a strong U.S. commercial footprint. The combination of in-house manufacturing plus a partnership/portfolio-extension model closely mirrors Aggrega's consortium-led approach.
• Lannett Company: Lannett is a U.S.-focused generic drug developer and manufacturer with a portfolio spanning oral solids, injectables and ophthalmics. It is comparable as a mid-sized generic manufacturer pursuing complex generics and partnership-led distribution into the U.S. market.
• Apotex: Apotex is one of the largest privately held Canadian generic pharmaceutical manufacturers with a broad portfolio across dosage forms and global reach. Like Aggrega, it is private and uses in-house manufacturing plus partnerships to expand its generic and complex-generic pipeline.
• Endo International (Par Health): Par Pharmaceutical (Endo's generics arm) is a U.S. generic manufacturer with strong positions in sterile injectables, ophthalmics and complex generics. It directly overlaps with the Substipharm- and Welding-sourced capabilities Aggrega uses to win U.S. partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aggrega-pharma-lcc

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aggrega Pharma